Cetrorelix is filed as GnRH antagonist. The sections below restate public label fields stored for this profile.
Cetrotide ® (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrotide ® competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. The onset of LH suppression is approximately one hour with the 3 mg dose and two hours with the 0.25 mg dose. This suppression is maintained by continuous treatment and there is a more pronounced effect on LH than on FSH. An initial release of endogenous gonadotropins has not been detected with Cetrotide ® , which is consistent with an antagonist effect. The effects of Cetrotide ® on LH and FSH are reversible after discontinuation of treatment. In women, Cetrotide ® delays the LH-surge, and consequently ovulation, in a dose-dependent fashion. FSH levels are not affected at the doses used during controlled ovarian stimulation. Following a single 3 mg dose of Cetrotide ® , duration of action of at least 4 days has been established. A dose of Cetrotide ® 0.25 mg every 24 hours has been shown to maintain the effect.
Cetrotide ® (cetrorelix acetate for injection) should be prescribed by physicians who are experienced in fertility treatment. Before starting treatment with Cetrotide ® , pregnancy must be excluded (see CONTRAINDICATIONS and PRECAUTIONS ).
Cetrotide ® (cetrorelix acetate for injection) is contraindicated under the following conditions: Hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol. Known hypersensitivity to GnRH or any other GnRH analogs. Known or suspected pregnancy, and lactation (see PRECAUTIONS ). Severe renal impairment
The safety of Cetrotide ® (cetrorelix acetate for injection) in 949 patients undergoing controlled ovarian stimulation in clinical studies was evaluated. Women were between 19 and 40 years of age (mean: 32). 94.0% of them were Caucasian. Cetrotide ® was given in doses ranging from 0.1 mg to 5 mg as either a single or multiple dose. Table 3 shows systemic adverse events, reported in clinical studies without regard to causality, from the beginning of Cetrotide ® treatment until confirmation of pregnancy by ultrasound at an incidence ≥ 1% in Cetrotide ® treated subjects undergoing COS. Table 3: Adverse Events in ≥1% (WHO preferred term) Cetrotide ® N=949 % (n) Ovarian Hyperstimulation Syndrome Intensity moderate or severe, or WHO Grade II or III, respectively 3.5 (33) Nausea 1.3 (12) Headache 1.1 (10) Local site reactions (e.g. redness, erythema, bruising, itching, swelling, and pruritus) were reported. Usually, they were of a transient nature, mild intensity and short duration. During post-marketing surveillance, cases of mild to moderate Ovarian Hyperstimulation syndrome and cases of hypersensitivity reactions including anaphylactoid reactions have been reported. Two stillbirths were reported in Phase 3 studies of Cetrotide ® .
Ovarian stimulation therapy with gonadotropins (FSH, hMG) is started on cycle Day 2 or 3. The dose of gonadotropins should be adjusted according to individual response. Cetrotide ® (cetrorelix acetate for injection) 0.25 mg may be administered subcutaneously once daily during the early- to mid-follicular phase. Cetrotide ® 0.25 mg is administered on either stimulation day 5 (morning or evening) or day 6 (morning) and continued daily until the day of hCG administration. When assessment by ultrasound shows a sufficient number of follicles of adequate size, hCG is administered to induce ovulation and final maturation of the oocytes. No hCG should be administered if the ovaries show an excessive response to the treatment with gonadotropins to reduce the chance of developing ovarian hyperstimulation syndrome (OHSS).
No formal drug interaction studies have been performed with Cetrotide ® .
According to its FDA label, Cetrorelix is approved for: Cetrotide ® (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. For medical advice, please talk to your prescriber or pharmacist.
Cetrorelix belongs to the GnRH antagonist class of medications.
The FDA label lists Cetrorelix as: HOW SUPPLIED Cetrorelix Acetate for Injection 0.25 mg is available in a carton of one packaged tray (NDC 60505-6270-1). Each packaged tray contains: one glass vial containing 0.26 to 0.27 mg cetrorelix acetate (corresponding to 0.25 mg cetrorelix) (Cetrorelix Acetate for Injection vial NDC 60505-6281-0), one pre-filled glass syringe with 1 mL of Sterile Water for Injection, (diluent syringe NDC 60505-6276-0), one 20 gauge needle (yellow) and one 27 gauge needle (grey). Storage Store cetrorelix acetate for injection 0.25 mg refrigerated, 2°C to 8°C (36°F to 46°F). Store the packaged tray in the outer carton in order to protect from light.; subcutaneous route. Available strengths and packaging vary by manufacturer.
Yes. A generic version of Cetrorelix is available in the U.S. Ask your pharmacist about substitution.
Our ingest of the FDA label for Cetrorelix does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
The FDA Enforcement Report does not show an active/ongoing recall for Cetrorelix in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA record lists the approval date for Cetrorelix as 2024-04-16.
The FDA label lists Apotex Corp. as a labeler/manufacturer of Cetrorelix. Multiple firms may market generics of the same molecule.
The FDA label states: "Cetrotide ® (cetrorelix acetate for injection) 0.25 mg is available in a carton of one packaged tray (NDC 44087-1225-1). Each packaged tray contains: one glass vial containing 0.26 - 0.27 mg cetrorelix acetate (correspon…" Follow the packaging insert for the authoritative guidance.
Loading full data from Know Your Drugs Institute…